INT280030

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.28
First Reported 2009
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 3
Disease Relevance 2.03
Pain Relevance 0.27

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (Dpp4) extracellular region (Dpp4) cell adhesion (Dpp4)
Golgi apparatus (Dpp4) endoplasmic reticulum (Dpp4) plasma membrane (Dpp4)
Anatomy Link Frequency
plasma 1
Dpp4 (Mus musculus)
Pain Link Frequency Relevance Heat
agonist 41 93.00 High High
tolerance 16 86.64 High High
cva 2 72.48 Quite High
pruritus 4 58.48 Quite High
abdominal pain 3 34.60 Quite Low
headache 4 27.72 Quite Low
Inflammation 10 5.00 Very Low Very Low Very Low
cytokine 4 5.00 Very Low Very Low Very Low
Neuropeptide 3 5.00 Very Low Very Low Very Low
Paracetamol 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Weight Loss 18 99.02 Very High Very High Very High
Hypoglycemia 88 97.92 Very High Very High Very High
Diabetes Mellitus 293 94.64 High High
Impaired Glucose Tolerance 14 87.28 High High
Pulmonary Embolism 2 72.48 Quite High
Heart Rate Under Development 18 71.32 Quite High
Pancreatitis 10 70.76 Quite High
Cholecystitis 2 70.08 Quite High
Vomiting 14 67.68 Quite High
Pruritus 4 58.48 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
However, unlike GLP-1, GIP does not inhibit glucagon secretion, does not slow gastric emptying, inhibit food intake, or promote weight loss.88 Both GLP-1 and GIP are rapid degraded by the DPP-4, which is ubiquitously present in plasma and on all cell membranes.
Localization (present) of DPP-4 in plasma associated with weight loss
1) Confidence 0.28 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941781 Disease Relevance 0.46 Pain Relevance 0.04
These clinical observations reinforce the mechanism of action of endogenously-secreted GLP-1 on insulin secretion as being glucose-dependent and demonstrate that, when the DPP-4 inhibitor alogliptin is administered with agents that do not augment insulin secretion, hypoglycemia is uncommon and does not occur more frequently than in the placebo group.
Localization (administered) of DPP-4 associated with hypoglycemia
2) Confidence 0.28 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941781 Disease Relevance 1.11 Pain Relevance 0.07
Albiglutide, a DPP-4-resistant GLP-1 analog which is administered weekly, reduced fasting and postprandial glucose levels without causing hypoglycemia in healthy subjects87 and T2DM patients.88 A dose of 32 mg reduced 24-hour mean weighted glucose by 35 mg/dL (?
Localization (analog) of DPP-4-resistant associated with hypoglycemia and diabetes mellitus
3) Confidence 0.26 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2731024 Disease Relevance 0.45 Pain Relevance 0.16

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox